Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;47(7):617-641.
doi: 10.1007/s40264-024-01415-7. Epub 2024 Apr 12.

Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy

Brandon W Lennep  1 , Jesse Mack  2 , Srinivasu Poondru  3 , Elizabeth Hood  1 , Brooke D Looney  4 , Monique Williams  5 , Judeth J Bianco  6 , Alicia K Morgans  7
Affiliations
Review

Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy

Brandon W Lennep et al. Drug Saf. 2024 Jul.

Abstract

Enzalutamide is an oral androgen receptor signaling inhibitor utilized in the treatment of men with prostate cancer. It is a moderate inducer of the cytochrome P450 (CYP) enzymes CYP2C9 and CYP2C19, and a strong inducer of CYP3A4. It was also shown to be a mild inhibitor of the efflux transporter P-glycoprotein in patients with prostate cancer. Enzalutamide is primarily metabolized by CYP3A4 and CYP2C8. The risk of enzalutamide drug interactions arises primarily when it is coadministered with other drugs that interact with these CYPs, including CYP3A4. In this review, we begin by providing an overview of enzalutamide including its dosing, use in special populations, pharmacokinetics, changes to its prescribing information, and potential for interaction with coadministered drugs. Enzalutamide interactions with drugs from a wide range of medication classes commonly prescribed to patients with prostate cancer are described, including oral androgen deprivation therapy, agents used to treat a range of cardiovascular diseases, antidiabetic drugs, antidepressants, anti-seizure medications, common urology medications, analgesics, proton pump inhibitors, immunosuppressants, and antigout drugs. Enzalutamide interactions with common vitamins and supplements are also briefly discussed. This review provides a resource for healthcare practitioners and patients that will help provide a basis for the understanding and management of enzalutamide drug-drug interactions to inform decision making, improve patient safety, and optimize drug efficacy.

Plain language summary

Enzalutamide is a drug that is used to treat various stages of advanced prostate cancer, a type of cancer that begins in the prostate and may spread beyond the prostate. Enzalutamide stops testosterone from stimulating prostate cancer growth. Like other drugs, enzalutamide enters the bloodstream, and then is processed and removed from the body. Sometimes, when a person takes multiple drugs, one drug can make it difficult for the body to process and remove one or more of the other drugs. This is referred to as a drug interaction. Enzalutamide drug interactions can cause the level of other drugs in the body to increase or decrease in an abnormal way. It is also possible for certain other drugs to alter the levels of enzalutamide. Drug interactions that cause the level of a drug to get too low can prevent that drug from working effectively, whereas drug interactions that cause the level of a drug to get too high can lead to side effects of that drug. People with prostate cancer are mostly aged 65 years or older and often take medications to treat a variety of diseases. Examples include medications to treat heart conditions, diabetes, high cholesterol, high blood pressure, and many other conditions. Here, we describe enzalutamide drug interactions with these types of medications. Our goal is to provide a resource to help healthcare providers and patients better understand enzalutamide drug interactions and how to manage them to improve patient safety and drug effectiveness.

PubMed Disclaimer

Conflict of interest statement

Brandon Lennep has received consulting fees from Pfizer Inc. Jesse Mack is an employee of Astellas Pharma Inc. and was a consultant for Pfizer prior to joining Astellas Pharma Inc. Srinivasu Poondru is an employee of Astellas Pharma Inc. Brooke Looney receives research support from AstraZeneca Inc. and Pfizer Inc. and has served as a speaker for AstraZeneca Inc. Judeth Bianco is an employee of Pfizer Inc. Alicia Morgans has received consulting fees from Astellas Pharma Inc., AAA Pharma Inc., AstraZeneca Pharma LP, Bayer HealthCare Pharma LLC, Dendreon Pharma LLC, Janssen Pharma LLC, Exelixis Inc., Myovant Sciences, Inc., Merck & Co. Inc., Novartis AG, Lantheus, Telix Pharma Limited, Sanofi S.A., and Pfizer Inc., research fees from Bayer HealthCare Pharma LLC, Myovant Sciences Inc., and Pfizer Inc., and travel support from Telix Pharma Limited and Sanofi S.A. Elizabeth Hood and Monique Williams have no financial interests to declare.

Figures

Fig. 1
Fig. 1
Enzalutamide clinical drug interaction studies. Enzalutamide is metabolized by CYP2C8 and CYP3A4. Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer. Enzalutamide was shown to be a mild inhibitor of human P-gp. AUC area under the curve (systemic drug exposure), Cmax maximum concentration after a single dose, CYP cytochrome P450, P-gp P-glycoprotein, PI prescribing information
Fig. 2
Fig. 2
Enzalutamide with anticoagulants and antiplatelet agents
Fig. 3
Fig. 3
Complex interactions between enzalutamide and clopidogrel. CYP cytochrome P450
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Prostate Cancer 2022. Available from: https://seer.cancer.gov/statfacts/html/prost.html. Accessed 10 Apr 2023.
    1. Chin HW, Kim J, Rasp G, Hristov B. Prostate cancer in seniors: part 1: epidemiology, pathology, and screening. Fed Pract. 2015;32(Suppl. 4):41S–44S. - PMC - PubMed
    1. Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29(2):377–385. doi: 10.1093/annonc/mdx742. - DOI - PubMed
    1. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74. doi: 10.1186/s12916-015-0322-7. - DOI - PMC - PubMed

MeSH terms